OncoMatch/Clinical Trials/NCT06510361
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
Is NCT06510361 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Epcoritamab for lymphoma.
Treatment: Epcoritamab — This research is being done to see if epcoritamab is effective in treating follicular lymphoma as a second line of treatment. The name of the study drug in this research study is: -Epcoritamab (a type of antibody)
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Cancer type
Non-Hodgkin Lymphoma
Biomarker criteria
Required: CD20 positive (by immunophenotype or immunohistochemistry) at time of diagnosis (all degrees of CD20 positivity accepted)
follicular lymphoma grade 1-3A that is CD20+ (by immunophenotype or immunohistochemistry) at time of diagnosis. All degrees of CD20 positivity will be accepted.
Disease stage
Required: Stage III, IV
Grade: 123a
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: anti-CD20 antibody combined with chemotherapy (obinutuzumab, rituximab, bendamustine, CHOP, CVP, lenalidomide) — upfront or first-line
1 prior line (at least 3 cycles) of systemic "upfront" or first-line therapy consisting of anti-CD20 antibody (e.g. obinutuzumab or rituximab) combined with chemotherapy (e.g. bendamustine, CHOP, CVP, or lenalidomide). Rituximab monotherapy, rituximab plus radiation, or radiation alone is not sufficient.
Cannot have received: rituximab monotherapy (rituximab)
Rituximab monotherapy, rituximab plus radiation, or radiation alone is not sufficient.
Cannot have received: investigational agent
Use of investigational agents incorporated into prior induction therapy
Lab requirements
Blood counts
Absolute neutrophil count ≥1000 cells/mcl (G-CSF allowed if marrow involved); Platelets ≥75,000 cells/mcl (transfusion allowed if marrow involved); Hemoglobin ≥ 8 g/dL (transfusion allowed if marrow involved)
Kidney function
Creatinine ≤ institutional ULN OR creatinine clearance > 45 ml/min (by Cockcroft-Gault estimate or 24-hr creatinine clearance measurement)
Liver function
Total bilirubin ≤ 1.5 institutional ULN (≤3x ULN if Gilbert's disease); AST(SGOT)/ALT(SGPT) ≤3× institutional ULN unless suspected/known involvement by follicular lymphoma
Cardiac function
EF ≥45%
Participants must meet the following organ and marrow function as defined below: Absolute neutrophil count ≥1000 cells/mcl (G-CSF allowed if marrow involved with disease); Platelets ≥75,000 cells/mcl (transfusion allowed if marrow involved); Hemoglobin ≥ 8 g/dL (transfusion allowed if marrow involved); Total bilirubin ≤ 1.5 institutional upper limit of normal (ULN). In patients with suspected/known Gilbert's disease total bilirubin up to 3x ULN will be allowed; AST(SGOT)/ALT(SGPT) ≤3× institutional ULN unless suspected/known involvement by follicular lymphoma; Creatinine ≤ institutional ULN OR creatinine clearance > 45 ml/min (by Cockcroft-Gault estimate or 24-hr creatinine clearance measurement); EF <45% or need for supplemental O2 at rest to maintain SaO2>89% [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Stanford · Stanford, California
- Beth Israel Deaconess Medical Center · Boston, Massachusetts
- Icahn School of Medicine at Mount Sinai · New York, New York
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06510361 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior rituximab monotherapy, investigational agent disqualifies patients from enrollment.
Does this trial require CD20?
Yes, CD20 positive (by immunophenotype or immunohistochemistry) at time of diagnosis is a required biomarker for enrollment.
What disease stage is eligible?
Stage III or IV is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages